Colorectal Cancer, Synchronous Isolated Para-aortic Lymph Node Metastasis
Conditions
Brief summary
The study aims to estimate the efficacy and safety of systemic therapy sequenced radical surgery in treating patients with synchronous isolated para-aortic lymph node metastasis of colorectal cancer.
Detailed description
Patients with synchrnous isolated para-aortic lymph node metastasis of colorectal cancer receiving systemtic therapy (at most two lines), radiologically assessed efficacious, and assessed by MDT that are potential to reach no evidence of disease (NED) were included in our trial. All included patients receive para-aortic lymph node dissection.
Interventions
PROCEDUREPara-aortic lymph node dissection
Para-aortic lymph node dissection was defined as the dissection of para-aortic lymph nodes located below renal vein and above the bifurcation of iliac artery.
Sponsors
First Affiliated Hospital of Zhejiang University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age at enrollment is \>= 18 and \<= 75 years 2. ECOG PS 0-1 3. Histologically confirmed colorectal carcinoma 4. Synchronous metastatic colorectal cancer with isolated para-aortic lymph node metastases: In the preoperative examination of positron emission tomography CT and abdominopelvic CT, metastasis was noted when the diameter of the PALN was 10 mm or greater and had irregular shape. 5. Single-organ para-aortic lymph node metastasis (PLANM) who are potential to receive surgery and achieve no evidence of disease (NED). 6. Adequate liver, renal and bona marrow function. 7. Signing written informed consent
Exclusion criteria
1. In addition to PALN metastasis, distant metastases such as lung, liver, peritoneum and bone were presen and in instances when the renal vein was in the upward spread path of the LN metastasis. 2. Unable to achieve NED 3. Clinically severe (ie, active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or severe arrhythmia requiring medication intervention, Or a history of myocardial infarction in the last 12 months. 4. Those with other history of malignant disease in the last 5 years, except for cured skin cancer and cervical carcinoma in situ. 5. Organ transplantation requires immunosuppressive therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3-year DFS | From date of recruiment until the date of disease recurrece, assessed up to 3 years | Time with no recurrence of the diseases. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 5-year OS | Up to 5 years | From date of recruitment until the date of death from any cause, assessed up to 5 years. |
| LFS | From date of recruiment until the date of paraaortic lymph node recurrece, assessed up to 5 years | Time with no recurrence of the paraaortic lymph node region. |
| 1-year DFS | From date of recruiment until the date of disease recurrece, assessed up to 1 years | Time with no recurrence of the diseases. |
Countries
China
Contacts
Primary ContactGuosheng Wu, MD
Outcome results
None listed